Non-uroselective and uroselective α1-adrenolitics in everyday urological practice – the duel Review article
Article Sidebar
Published:
Sep 30, 2020
Keywords:
doxazosin, tamsulosin, benign prostatic hyperplasia, α1-adrenolitics
Main Article Content
Abstract
α1-adrenolitics are often considered the first-line treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) due to their quick onset of action, good efficacy and low frequency and severity of side effects. α1-adrenolitics are divided into non-uroselective and uroselective. The study compared two drugs, such as doxazosin and tamsulosin. The presented duel and its result may help in choosing the best treatment option for a specific patient with benign prostatic hyperplasia.
Article Details
How to Cite
Juszczak , K., & Drewa, T. (2020). Non-uroselective and uroselective α1-adrenolitics in everyday urological practice – the duel. Medycyna Faktow (J EBM), 13(3(48), 275-278. https://doi.org/10.24292/01.MF.0320.1
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. EAU Guidelines. Management of Non-neurogenic Male LUTS. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.
2. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64: 1081-8.
3. Barendrecht MM, Abrams P, Schumacher H et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008; 27(3): 226-30.
4. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64(6): 1144-8.
5. Forray C, Bard JA, Wetzel JM et al. The alpha1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacologic properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994; 45: 703-8.
6. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000; 283: 1967-75.
7. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled dose response multicenter study. J Urol. 1995; 154: 110-5.
8. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998; 51(6): 901-6.
9. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97(suppl 2): 34-8; discussion 44-5.
10. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005; 31: 664-73.
11. Narayan P, Lowe FC. The effects of tamsulosin on vital signs in two multicenter, placebo-controlled studies. Cardiovasc Rev Rep. 2000; 21: 494-9.
2. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64: 1081-8.
3. Barendrecht MM, Abrams P, Schumacher H et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008; 27(3): 226-30.
4. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64(6): 1144-8.
5. Forray C, Bard JA, Wetzel JM et al. The alpha1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacologic properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994; 45: 703-8.
6. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000; 283: 1967-75.
7. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled dose response multicenter study. J Urol. 1995; 154: 110-5.
8. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998; 51(6): 901-6.
9. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97(suppl 2): 34-8; discussion 44-5.
10. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005; 31: 664-73.
11. Narayan P, Lowe FC. The effects of tamsulosin on vital signs in two multicenter, placebo-controlled studies. Cardiovasc Rev Rep. 2000; 21: 494-9.